Drug Trial Radar · NCT07528053
A Phase 1 Clinical Study of BW-20805-2-1001 in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Apr 28, 2026
Primary completion
Jun 30, 2026
Study completion Nov 5, 2027
Sponsor
- Lead sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1 Clinical Study Of BW-20805-2-1001 in Healthy Participants
Conditions
- HV
Interventions
BW-20805Drug
Cohort 1 will receive SC administrations of BW-20805 on Day1.
BW-20805Drug
Group 2 will receive SC administrations of BW-20805 on Day1
BW-20805-2Drug
Group 3 will receive SC administrations of BW-20805-2 on Day1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary EndpointsTime frame: week 48
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Argo Investigative Site
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.